Glee Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-10-2024
- Paid Up Capital ₹ 0.50 M
as on 31-10-2024
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.69 M
as on 31-10-2024
- Revenue 9.73%
(FY 2023)
- Profit 64.89%
(FY 2023)
- Ebitda 86.57%
(FY 2023)
- Net Worth 106.92%
(FY 2023)
- Total Assets 100.43%
(FY 2023)
About Glee Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.69 M.
Rachna Bhatia, Raghav Bhatia, Kiran Bhatia, and One other member serve as directors at the Company.
- CIN/LLPIN
U33100DL2020PLC362536
- Company No.
362536
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
03 Mar 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Glee Biotech Limited offer?
Glee Biotech Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Anti Allergic Drug, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs.
Who are the key members and board of directors at Glee Biotech?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rachna Bhatia  | Director | 03-Mar-2020 | Current |
| Raghav Bhatia | Director | 03-Mar-2020 | Current |
| Kiran Bhatia | Director | 08-Dec-2020 | Current |
| Vikas Khatri | Director | Current |
Financial Performance of Glee Biotech.
Glee Biotech Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.73% increase. The company also saw a substantial improvement in profitability, with a 64.89% increase in profit. The company's net worth Soared by an impressive increase of 106.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Glee Biotech?
In 2023, Glee Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 23 May 2023 | ₹0.95 M | Open |
Hdfc Bank Limited Creation Date: 06 Sep 2022 | ₹3.73 M | Open |
How Many Employees Work at Glee Biotech?
Unlock and access historical data on people associated with Glee Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glee Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glee Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
